DiscoveryProbe™ FDA-approved Drug Library: A New Era in High-Throughput Screening and Drug Repositioning

Principle and Setup: Unlocking the Power of a Clinically Vetted Compound Collection

The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) is a meticulously curated portfolio of 2,320 bioactive compounds, each with a proven clinical track record and regulatory approval from agencies including the FDA, EMA, HMA, CFDA, and PMDA. This FDA-approved bioactive compound library is designed to empower researchers across disciplines by offering a diverse array of compounds spanning receptor agonists/antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. The library's pre-dissolved 10 mM DMSO format—available in 96-well, deep-well, and 2D barcoded tube formats—greatly simplifies integration into high-throughput screening (HTS) and high-content screening (HCS) workflows, while ensuring sample stability for up to 24 months at -80°C.

This collection is purpose-built for applications including, but not limited to: drug repositioning screening, pharmacological target identification, cancer research drug screening, neurodegenerative disease drug discovery, signal pathway regulation, and enzyme inhibitor screening. Extensive representation of clinically relevant entities—such as doxorubicin, metformin, and atorvastatin—makes it a versatile tool for both fundamental research and translational innovation.

Step-by-Step Workflow: Streamlining HTS and HCS with Ready-to-Deploy Solutions

1. Plate Preparation and Compound Handling

• Thawing and Equilibration: Retrieve plates or tubes from -20°C (or -80°C for long-term storage) and equilibrate to room temperature. The DMSO-based solutions are ready to use, eliminating the need for time-consuming reconstitution or solubilization.
• Plate Layout and Controls: Design your assay plate layout for optimal data normalization—include positive controls (e.g., a reference inhibitor) and negative/vehicle (DMSO) controls across columns or quadrants. The 2D barcoding facilitates robust sample tracking, critical when scaling to hundreds of compounds per run.

2. Assay Integration

• Cell-Based and Biochemical Assays: The library’s compatibility with diverse readouts (luminescence, fluorescence, absorbance) enables flexible deployment across cell viability, reporter gene, enzyme inhibition, and pathway activation screens.
• Automation: The uniform 10 mM concentration and microplate format are ideal for liquid handling platforms, minimizing pipetting errors and supporting automated serial dilution schemes.

3. Screening and Data Acquisition

• High-Throughput Execution: The library has been successfully implemented in advanced TR-FRET assays, such as those used to identify the first small-molecule inhibitors of the ICOS/ICOSL immune checkpoint pathway (Abdel-Rahman et al., 2023), demonstrating robust compatibility with modern HTS platforms.
• Data Analysis: Leverage integrated informatics to rapidly triage hits, compare dose-response curves, and prioritize compounds for secondary screening or mechanistic follow-up.

4. Hit Validation and Follow-Up

• Orthogonal Assays: Confirm activity using independent assay formats (e.g., switch from TR-FRET to bioluminescent co-culture for immune checkpoint modulation, as exemplified in the cited ICOS/ICOSL study).
• Structure-Activity Relationship (SAR): Utilize the well-annotated compound metadata to cluster hits by mechanism and perform targeted SAR analysis, accelerating the path to lead optimization.

Advanced Applications and Comparative Advantages

Cancer and Neurodegenerative Disease Paradigms

The DiscoveryProbe FDA-approved Drug Library stands out for its proven value in oncology and neurodegeneration research. In recent work, the library enabled HTS of small molecules for inhibition of the ICOS/ICOSL immune checkpoint, which is pivotal for overcoming immune resistance in cancer therapy. Small molecules identified from this library, such as AG-120-X (IC₅₀ = 4.68 ± 0.47 µM in TR-FRET), demonstrated potent, dose-dependent activity in both biochemical and cellular models, highlighting the library’s capacity to drive first-in-class discoveries where monoclonal antibodies fall short.

Beyond oncology, the collection accelerates neurodegenerative disease drug discovery by enabling rapid screening for modulators of signaling pathways implicated in neuroprotection, inflammation, and synaptic plasticity. The high-content screening compound collection thus supports integrated phenotypic and target-based approaches, as highlighted in recent translational case studies (which complement the present workflow by demonstrating real-world implementation in rare disease models).

Speed and Cost-Efficiency in Drug Repositioning

Drug repositioning screening is uniquely streamlined by the library’s inclusion of only clinically validated entities, reducing the translational gap from bench to clinic. As detailed in complementary resources, leveraging this high-throughput screening drug library can cut lead discovery timelines by months, yielding actionable candidates for repurposing in areas such as COVID-19, oncology, and CNS disorders.

Integration with Structural and Pathway-Based Research

The library’s comprehensive annotation of mechanisms enables high-resolution pharmacological target identification and supports advanced signal pathway regulation studies. For example, in GPCR and kinase-targeted campaigns, as explored in this comparative review, the DiscoveryProbe™ FDA-approved Drug Library extends conventional target-based screens with pathway-focused insights, facilitating polypharmacology and network pharmacology research.

Troubleshooting and Optimization: Maximizing Data Quality

• DMSO Compatibility: While most cell lines tolerate ≤0.1% DMSO, some primary and sensitive cells may exhibit toxicity. Pre-validate assay DMSO tolerance and, if necessary, dilute compounds to maintain DMSO at or below threshold levels.
• Edge Effects in Plate-Based Assays: Use plate sealers and minimize evaporation by equilibrating plates in a humidified chamber pre- and post-compound addition. Randomize hit compounds across plates to detect and correct for positional bias.
• Compound Stability: Thaw only the number of wells needed per experiment and minimize freeze-thaw cycles. For prolonged studies, aliquot compounds into single-use plates to preserve integrity.
• Data Normalization and Hit Selection: Include robust internal controls and replicate wells. Use Z'-factor calculations (values >0.5 indicate excellent assay quality) to validate screen performance.
• False Positives/Negatives: Confirm activity in orthogonal assay formats, and where possible, implement counter-screens to exclude pan-assay interference compounds (PAINS).

Future Outlook: Next-Generation Screening and Translational Impact

The DiscoveryProbe™ FDA-approved Drug Library is continually updated to reflect the evolving landscape of clinical pharmacology and regulatory approvals. Its integration with automated HTS/HCS platforms and informatics pipelines will further reduce the time from target hypothesis to validated hit. As precision medicine initiatives and systems pharmacology approaches gain traction, this library’s unique capacity for signal pathway regulation and enzyme inhibitor screening will underpin not only the discovery of new therapeutics but also the de-risking of clinical development through early identification of on- and off-target effects.

Moreover, as demonstrated by the successful identification of small-molecule ICOS/ICOSL inhibitors (Abdel-Rahman et al., 2023), the library facilitates the exploration of emerging therapeutic modalities and combination strategies that transcend the limitations of monoclonal antibodies. Its broad utility—spanning cancer, neurodegeneration, rare diseases, and more—positions the DiscoveryProbe™ FDA-approved Drug Library as an indispensable tool for next-generation drug discovery and translational research worldwide.